J. Goldman & CO LP Intra Cellular Therapies, Inc. Transaction History

J. Goldman & CO LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $4.92 Million - $7.81 Million	106,080 New	106,080 $7.6 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $3.04 Million - $3.69 Million	55,595 New	55,595 $3.52 Million
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $293,842 - $470,952	-7,585 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $600,406 - $911,184	-17,057 Reduced 69.22%	7,585 $397,000
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $1.19 Million - $1.77 Million	-41,590 Reduced 62.79%	24,642 $919,000
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $1.87 Million - $2.84 Million	-63,800 Reduced 49.06%	66,232 $2.7 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $21,744 - $27,894	706 Added 0.55%	130,032 $4.41 Million
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $3.02 Million - $4.17 Million	129,326 New	129,326 $4.11 Million
Q1 2018 May 15, 2018	SELL	$15.16 - $25.49 $3.78 Million - $6.35 Million	-249,274 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $1.97 Million - $2.32 Million	138,374 Added 124.77%	249,274 $3.61 Million
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $1.19 Million - $2.45 Million	110,900	110,900 $1.75 Million

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.